Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 19, 2026, 8:04 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 48 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Delayed Effects Plus Dose Clear all
Completed Phase 1 Interventional Results available

Safety, Tolerability and Pharmacokinetic (PK) of Concomitant Esomeprazole and Rifampin, and QT Study on Single and Multiple-doses of Alisertib

NCT01844583
View directory record Official record
Conditions
Solid Tumors, Lymphoma
Interventions
Alisertib, Esomeprazole, Rifampin
Drug
Lead sponsor
Millennium Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older
Enrollment
55 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
7
States / cities
Sarasota, Florida • St Louis, Missouri • Oklahoma City, Oklahoma + 4 more
Source: ClinicalTrials.gov public record
Updated Mar 25, 2019 · Synced Oct 19, 2026, 8:04 AM EDT
Withdrawn Phase 4 Interventional

Dose Clinical Trial of Guanfacine Extended Release for the Reduction of Aggression and Self-injuries Behavior Associated With Prader-Willi Syndrome

NCT04066088
View directory record Official record
Conditions
Prader-Willi Syndrome
Interventions
Placebo, Guanfacine extended release (GXR)
Other · Drug
Lead sponsor
NYU Langone Health
Other
Eligibility
6 Years to 35 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Aug 26, 2020 · Synced Oct 19, 2026, 8:04 AM EDT
Active, not recruiting Phase 4 Interventional

Long-term Effectiveness of the Antiobesity Medication Phentermine

NCT05176626
View directory record Official record
Conditions
Obesity, Obesity; Drug, Lifestyle, Healthy
Interventions
Online Lifestyle Behavioral Therapy, Phentermine Hydrochloride 8 MG
Behavioral · Drug
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
18 Years to 70 Years
Enrollment
870 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
4
States / cities
Los Angeles, California • Saint Louis Park, Minnesota • Winston-Salem, North Carolina + 1 more
Source: ClinicalTrials.gov public record
Updated Mar 31, 2026 · Synced Oct 19, 2026, 8:04 AM EDT
Suspended Phase 3 Interventional

Investigational Study of Delayed Release Metformin

NCT04854512
View directory record Official record
Conditions
Diabetes Mellitus, Type 2
Interventions
Metformin DR, Metformin IR, Metformin DR Placebo, Metformin IR placebo
Drug
Lead sponsor
Anji Pharma
Industry
Eligibility
18 Years to 100 Years
Enrollment
675 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
33
States / cities
Glendale, Arizona • Mesa, Arizona • Apple Valley, California + 30 more
Source: ClinicalTrials.gov public record
Updated Mar 14, 2023 · Synced Oct 19, 2026, 8:04 AM EDT
Not listed Phase 4 Interventional

Effect of Ranolazine on Activity Level in Patients With Angina After FFR Based Deferred Intervention (REPTAR)

NCT03044964
View directory record Official record
Conditions
Angina
Interventions
Ranolazine, Placebo
Drug
Lead sponsor
Amit Malhotra, MD
Industry
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017
U.S. locations
1
States / cities
Southaven, Mississippi
Source: ClinicalTrials.gov public record
Updated Feb 7, 2017 · Synced Oct 19, 2026, 8:04 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Comparison of Depression Interventions After Acute Coronary Syndrome

NCT01032018
View directory record Official record
Conditions
Acute Coronary Syndrome, Depression
Interventions
Problem Solving Therapy, Sertraline, citalopram, or bupropion, Standard care
Behavioral · Drug · Other
Lead sponsor
Columbia University
Other
Eligibility
35 Years and older
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
5
States / cities
New Haven, Connecticut • Atlanta, Georgia • St Louis, Missouri + 2 more
Source: ClinicalTrials.gov public record
Updated Sep 13, 2017 · Synced Oct 19, 2026, 8:04 AM EDT
Recruiting Phase 2 Interventional

Phase 2 EL219 Versus Liposomal Amphotericin B or Voriconazole for Early Antifungal Therapy

NCT07215273
View directory record Official record
Conditions
Invasive Mould Infection
Interventions
EL219, Active Comparator- IV Antifungal (LAmB or voriconazole)
Drug
Lead sponsor
Elion Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026
U.S. locations
10
States / cities
Birmingham, Alabama • Sacramento, California • Augusta, Georgia + 7 more
Source: ClinicalTrials.gov public record
Updated Oct 5, 2026 · Synced Oct 19, 2026, 8:04 AM EDT
Active, not recruiting Phase 4 Interventional

Effects of the Contraceptive Implant in Women With Sickle Cell Disease

NCT05730205
View directory record Official record
Conditions
Sickle Cell Disease
Interventions
Nexplanon 68 MG Drug Implant
Drug
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years to 45 Years · Female only
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jun 12, 2026 · Synced Oct 19, 2026, 8:04 AM EDT
Completed Early Phase 1 Interventional Accepts healthy volunteers

Follicle-Stimulating Hormone (FSH) and the Onset of Puberty

NCT00734279
View directory record Official record
Conditions
Delayed Puberty, Precocious Puberty
Interventions
Leuprolide Acetate - Early Puberty Leuprolide Visit, Ganirelix - Early Puberty Ganirelix Visit, Ganirelix - Delayed Puberty Ganirelix Visit, Leuprolide Acetate- Delayed Puberty Leuprolide Visit
Drug
Lead sponsor
University of Utah
Other
Eligibility
6 Years to 17 Years
Enrollment
11 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2010
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Dec 26, 2017 · Synced Oct 19, 2026, 8:04 AM EDT
Recruiting Phase 4 Interventional Accepts healthy volunteers

Stimulant Effects on Disruptive Behavior

NCT03420339
View directory record Official record
Conditions
Attention Deficit Hyperactivity Disorder, Problem Behavior
Interventions
Stimulant
Drug
Lead sponsor
Matthew J O'Brien, PhD, BCBA-D
Other
Eligibility
48 Months to 12 Years
Enrollment
10 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2027
U.S. locations
1
States / cities
Iowa City, Iowa
Source: ClinicalTrials.gov public record
Updated Mar 17, 2025 · Synced Oct 19, 2026, 8:04 AM EDT
Completed Not applicable Interventional Results available

Rhode Island Diastolic Dysfunction - Heart Failure

NCT02353312
View directory record Official record
Conditions
Heart Failure, Cardiovascular Disease
Interventions
Kuvan
Drug
Lead sponsor
Providence VA Medical Center
Federal
Eligibility
18 Years and older
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
1
States / cities
Providence, Rhode Island
Source: ClinicalTrials.gov public record
Updated Jul 3, 2025 · Synced Oct 19, 2026, 8:04 AM EDT
Completed Phase 2 Interventional

A Study of Delayed and Extended Release Formulation of Dextroamphetamine Sulfate (HLD100) in Children With ADHD

NCT02884544
View directory record Official record
Conditions
Attention-Deficit Hyperactivity Disorder (ADHD)
Interventions
HLD100
Drug
Lead sponsor
Ironshore Pharmaceuticals and Development, Inc
Other
Eligibility
6 Years to 12 Years
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016
U.S. locations
1
States / cities
Las Vegas, Nevada
Source: ClinicalTrials.gov public record
Updated Jul 19, 2021 · Synced Oct 19, 2026, 8:04 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Compare Bioavailability of AZD5055 Film-coated Tablet With AZD5055 Oral Suspension and to Assess the Effect of Food and an Acid Reducing Agent on Pharmacokinetics (PK) of AZD5055 in Healthy Subjects.

NCT05630677
View directory record Official record
Conditions
Healthy Volunteers
Interventions
AZD5055 solution for infusion, AZD5055 oral suspension, AZD5055 film-coated tablet, Rabeprazole, Delayed-release tablet
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 55 Years
Enrollment
21 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2023
U.S. locations
1
States / cities
Brooklyn, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 4, 2024 · Synced Oct 19, 2026, 8:04 AM EDT
Terminated Phase 1Phase 2 Interventional

Study of Labetuzumab Govitecan in Participants With Metastatic Colorectal Cancer

NCT01605318
View directory record Official record
Conditions
Metastatic Colorectal Cancer, Colon Cancer, Rectal Cancer
Interventions
Labetuzumab Govitecan (LG)
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years and older
Enrollment
92 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2017
U.S. locations
7
States / cities
Santa Monica, California • Aurora, Colorado • Newark, Delaware + 4 more
Source: ClinicalTrials.gov public record
Updated Jan 24, 2024 · Synced Oct 19, 2026, 8:04 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A 5-Period, Single Dose, Phase 1 Study in Healthy Elderly Subjects to Assess Relative Bioavailability and Food Effect of Two Oral Formulations of GSK1325756 (Free Base vs HBr Salt) and Food Effect on the HBr Formulation When Given With Omeprazole

NCT02453022
View directory record Official record
Conditions
Pulmonary Disease, Chronic Obstructive
Interventions
Danirixin HBr 50 mg IR Tablet, Danirixin FB 50 mg IR Tablet, Prilosec (omeprazole) 40mg Delayed-Release capsule
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
65 Years to 80 Years
Enrollment
18 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015
U.S. locations
1
States / cities
Overland Park, Kansas
Source: ClinicalTrials.gov public record
Updated Jul 24, 2018 · Synced Oct 19, 2026, 8:04 AM EDT
Completed Phase 4 Interventional

Guanfacine Extended Release for the Reduction of Aggression and Self-injurious Behavior Associated With Prader-Willi Syndrome

NCT05657860
View directory record Official record
Conditions
Prader-Willi Syndrome, Aggression, Self-Injurious Behavior, Pathologic Processes, Behavioral Symptoms, Intellectual Disability, Neurobehavioral Manifestations, Neurologic Manifestations, Nervous System Diseases, Abnormalities, Multiple, Congenital Abnormalities, Chromosome Disorders, Genetic Diseases, Inborn, Obesity, Overnutrition, Nutrition Disorders, Antihypertensive Agents, Neurotransmitter Agents, Molecular Mechanisms of Pharmacological Action, Physiological Effects of Drugs, Skin-Picking
Interventions
Guanfacine Extended Release, Placebo
Drug · Other
Lead sponsor
Maimonides Medical Center
Other
Eligibility
6 Years to 35 Years
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
1
States / cities
Brooklyn, New York
Source: ClinicalTrials.gov public record
Updated Aug 19, 2024 · Synced Oct 19, 2026, 8:04 AM EDT
Terminated Phase 1 Interventional

Cardiac Allograft Remodeling and Effects of Sirolimus

NCT01889992
View directory record Official record
Conditions
Cardiac Hypertrophy, Immunosuppression
Interventions
Cardiac MRI, Coronary angiography with IVUS, Cardiac Allograft Remodeling, M-TOR Immunosuppression, Cardiac Biopsy C4D stain, Genetic Mechanism of M-TOR, Cardiopulmonary Exercise Test (CPET)
Radiation · Procedure · Other + 2 more
Lead sponsor
University of Nebraska
Other
Eligibility
19 Years to 70 Years
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2018
U.S. locations
1
States / cities
Omaha, Nebraska
Source: ClinicalTrials.gov public record
Updated Aug 30, 2023 · Synced Oct 19, 2026, 8:04 AM EDT
Terminated Phase 3 Interventional

Monoclonal Antibody Therapy in Treating Patients With Non-Hodgkin's Lymphoma

NCT00004874
View directory record Official record
Conditions
Lymphoma
Interventions
tositumomab and iodine I 131 tositumomab
Radiation
Lead sponsor
University of Nebraska
Other
Eligibility
19 Years to 120 Years
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1998 – 2012
U.S. locations
1
States / cities
Omaha, Nebraska
Source: ClinicalTrials.gov public record
Updated Jan 17, 2018 · Synced Oct 19, 2026, 8:04 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

GSK1325756 Relative Bioavailability Study in Healthy Elderly Subjects

NCT03457727
View directory record Official record
Conditions
Pulmonary Disease, Chronic Obstructive
Interventions
Danirixin, Omeprazole
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
65 Years to 80 Years
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018
U.S. locations
1
States / cities
Overland Park, Kansas
Source: ClinicalTrials.gov public record
Updated May 19, 2021 · Synced Oct 19, 2026, 8:04 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Perceptions of Proposed Warnings for Cannabis Edibles Packaging

NCT07496489
View directory record Official record
Conditions
Cannabis Use
Interventions
No Warning Control, Delayed Effects Text Only, Delayed Effects Plus Icon, Delayed Effects Plus Dose, Delayed Effects Plus Dose Plus Adverse Effects
Behavioral
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
18 Years to 65 Years
Enrollment
1,250 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026
U.S. locations
1
States / cities
Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated Oct 13, 2026 · Synced Oct 19, 2026, 8:04 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Evaluating the Effects of Omeprazole on the Pharmacokinetics of XS004 (Dasatinib) Tablets in Healthy Adult Subjects Under Fasting Conditions

NCT05433896
View directory record Official record
Conditions
Pharmacokinetics, Drug Interactions
Interventions
Dasatinib ASD, Omeprazole 40 MG
Drug
Lead sponsor
Xspray Pharma AB
Industry
Eligibility
18 Years to 60 Years
Enrollment
17 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020
U.S. locations
1
States / cities
Dilworth, Minnesota
Source: ClinicalTrials.gov public record
Updated Jun 27, 2022 · Synced Oct 19, 2026, 8:04 AM EDT
Completed Phase 3 Interventional Results available

A Study of the Safety and Efficacy of Two Doses of Naltrexone SR/Bupropion SR and Placebo in Overweight and Obese Subjects

NCT00532779
View directory record Official record
Conditions
Obesity, Overweight
Interventions
Naltrexone SR 16 mg/Bupropion SR 360 mg /day, Naltrexone SR 32 mg/Bupropion SR 360 mg /day, Placebo, Ancillary therapy
Drug · Behavioral
Lead sponsor
Orexigen Therapeutics, Inc
Industry
Eligibility
18 Years to 65 Years
Enrollment
1,742 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
34
States / cities
Birmingham, Alabama • Fairhope, Alabama • Chandler, Arizona + 28 more
Source: ClinicalTrials.gov public record
Updated Nov 21, 2014 · Synced Oct 19, 2026, 8:04 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Evaluate Platlet Aggregation of Clopidogrel, EC Aspirin 81 mg, EC Omeprazole 40 mg Compare to PA32540

NCT01557335
View directory record Official record
Conditions
Platelet Aggregation
Interventions
Plavix® and PA32540, EC aspirin (Bayer®) ,EC omeprazole (Prilosec®) , Clopidogrel (Plavix®)
Drug
Lead sponsor
POZEN
Industry
Eligibility
40 Years and older
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2011
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 19, 2012 · Synced Oct 19, 2026, 8:04 AM EDT
Completed Phase 4 Interventional Results available

Duloxetine Treatment in Elderly With Dysthymia

NCT01852383
View directory record Official record
Conditions
Depression, Dysthymic Disorder
Interventions
Duloxetine
Drug
Lead sponsor
New York State Psychiatric Institute
Other
Eligibility
60 Years to 95 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2013
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated May 1, 2014 · Synced Oct 19, 2026, 8:04 AM EDT